v-WIN Foundation and Alfasigma together to fight one of the leading causes of preventable death: venous thrombosis.
Italy as the hub of an international public awareness project on venous and lymphatic health of the legs to be presented in DUBAI during the EXPO.
An innovative geo-localization software has being launched to increase knowledge & awareness about the disease.
This year, Alfasigma will be Sponsor of the Vein Week, organized by v-WIN Foundation (Scientific Society in Phlebology). The initiative will take place from April, 5th to 11th and on the occasion, a Geomap Calendar software was developed, showing, within an interactive map, vascular events uploaded to the platform by the organizers themselves, upon approval of v-WIN Foundation.
Cosmo Pharmaceuticals will receive a €4m upfront payment Alfasigma plus double digit royalties.
Lumeblue™ was ecently approved by EMA for the detection of lesions during colonoscopy.
Alfasigma will distribute Lumeblue™ in EU, Switzerland, UK, European Economic Area countries, Russia and Mexico.
Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis).
Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies and ventricular arrhythmia are the main pathologies in which we offer solutions.
In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles.
With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue.
You’re entering Alfasigma global website
I agree